Under the partnership, Vial will support Nielsen for the Phase 3, randomised, double-blind, placebo-controlled clinical study of Candin for the treatment of common warts in adults in the US and Japan
A micrograph of common warts. (Credit: Nephron from Wikimedia Commons)
Contract research organisation (CRO) Vial has joined forces with US-based Nielsen BioSciences to evaluate the safety and efficacy of Candin for the treatment of common warts.
Nielsen is a biopharmaceutical company that develops and commercialises biological products with wide-ranging use of cell-mediated immune responses.
Under the partnership, Vial will support Nielsen for the Phase 3, randomised, double-blind, placebo-controlled clinical study of Candin for the treatment of Verruca vulgaris (common warts) in adults in the US and Japan.
Candin is said to be an approved diagnostic skin test. It is currently not cleared by the US Food and Drug Administration (FDA) or Japan’s Pharmaceuticals and Medical Devices Agency for the treatment of common warts.
Through the conclusion of Phase 3 clinical study, Vial’s Dermatology CRO will collaborate closely with the Nielsen Biosciences team.
Vial clinical operations senior director Wendy Pinson said: “Vial is thrilled to collaborate with Nielsen on their Phase 3 clinical trial in the US and Japan.
“We are committed to delivering high-quality trials powered by innovative technology that are affordable for sponsors. We have full confidence in our ability to drive optimal outcomes for this important study.”
Vial provides biotech sponsors with quicker, more effective trials at a reasonable price. Vial’s Dermatology CRO uses digital technology, such as its Vial Technology Platform, combining eSource, EDC, and ePRO in a single integrated system to streamline site processes.
Vial EDC is said to be an advanced and hyper-responsive EDC platform that gives eClinical software a consumer-grade experience and next-generation performance.
For sponsors and patients, these CRO services are expected to quicken the development of new treatments and medical equipment, the biopharmaceutical firm added.
Nielsen BioSciences president and COO David Burney said: “We look forward to partnering with the Vial team on Candin’s Phase III clinical trial.
“Our thoughtful discussion with their team, combined with an outstanding comprehensive presentation, gave us full confidence that this important clinical trial for common warts will be managed to the highest standards in the industry.”